Ina Oehme

This study compares ex vivo short-term, organoid, and PDX drug screening methods in neuroblastoma, finding ex vivo screens are faster and more consistent with in vivo results.

This study develops an ex vivo drug sensitivity testing platform for rare solid tumors and finds that high in vitro sensitivity correlates with clinical benefit and progression-free survival.

This study characterizes phenotypic plasticity in EGFR inhibitor-resistant NSCLC cell lines, showing diverse resistance mechanisms and metabolic adaptations across sublines.

This study develops MA191, a PROTAC degrader of FLT3-ITD, which overcomes resistance in AML cells by rapidly degrading the mutant protein and shows efficacy in vivo.

This study identifies GLRX3 as a vulnerability in Ewing sarcoma driven by EWSR1::FLI1 fusion oncoproteins, showing its role in oxidative stress and iron homeostasis and potential therapeutic targeting.